PMID- 31371390
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20211204
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Print)
IS  - 1081-5589 (Linking)
VI  - 68
IP  - 1
DP  - 2020 Jan
TI  - lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer.
PG  - 52-59
LID - 10.1136/jim-2019-001080 [doi]
AB  - Long non-coding RNAs (lncRNAs) have proved to act as crucial biomarkers in 
      tumors. Novel biomarkers in non-small cell lung cancer (NSCLC) need to be 
      investigated badly. To identify the differentially expressed lncRNAs between 
      NSCLC tissue and adjacent tissue, microarray analysis was performed. lncRNA 
      SLC16A1-AS1 was significantly less expressed in NSCLC tissue than that in 
      adjacent tissue. Gain-of-function experiments was performed to determine the 
      biological functions of SLC16A1-AS. In situhybridization and survival analysis 
      were applied in lung cancer tissue samples to determine the prognostic role of 
      SLC16A1-AS1. It was showed that SLC16A1-AS1 was remarkably downregulated in NSCLC 
      tissues and cell lines. Functionally, SLC16A1-AS1 overexpression could inhibit 
      the viability and proliferation of lung cancer cell, block the cell cycle and 
      promote cell apoptosis in vitro which may result from reduced phosphorylation of 
      rat sarcoma (RAS)/ proto-oncogene serine/threonine-protein kinase (RAF)/ 
      mitogen-activated protein kinase kinase (MEK)/ extracellular regulated protein 
      kinases (ERK) pathway caused by elevated expression of SLC16A1-AS1. Clinical 
      sample analysis showed that SLC16A1-AS1 had a favorable impact on the overall 
      survival and progression-free survival of patients with NSCLC. Our results 
      suggested that SLC16A1-AS1 may act as a potential biomarker for patients with 
      NSCLC.
CI  - (c) American Federation for Medical Research 2020. Re-use permitted under CC BY. 
      Published by BMJ.
FAU - Liu, Hong Yue
AU  - Liu HY
AD  - Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Lu, Sheng Rong
AU  - Lu SR
AD  - Department of Pharmacy, The Central Hospital of Min-Hang District, Shanghai, 
      China.
FAU - Guo, Zi Han
AU  - Guo ZH
AD  - Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Zhang, Zhi Sheng
AU  - Zhang ZS
AD  - Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Ye, Xuan
AU  - Ye X
AD  - Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Du, Qiong
AU  - Du Q
AD  - Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Li, Huan
AU  - Li H
AD  - Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Wu, Qiang
AU  - Wu Q
AD  - Department of Oncology, The Second Affiliated Hospital of Anhui Medical 
      University, Anhui, China.
FAU - Yu, Bo
AU  - Yu B
AD  - Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Zhai, Qing
AU  - Zhai Q
AD  - Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Liu, Jin Long
AU  - Liu JL
AUID- ORCID: 0000-0001-5574-6799
AD  - Department of Biotechnology and Pathology, School of Medical Technology, Shanghai 
      University of Medicine & Health Sciences, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190731
PL  - England
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American 
      Federation for Clinical Research
JID - 9501229
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Monocarboxylic Acid Transporters)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Symporters)
RN  - 0 (monocarboxylate transport protein 1)
SB  - IM
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/mortality
MH  - Cells, Cultured
MH  - Gene Expression Profiling
MH  - Humans
MH  - Lung Neoplasms/*genetics/mortality
MH  - Microarray Analysis
MH  - Monocarboxylic Acid Transporters/analysis/*genetics
MH  - Prognosis
MH  - Proto-Oncogene Mas
MH  - RNA, Long Noncoding/*analysis
MH  - Real-Time Polymerase Chain Reaction
MH  - Survival Analysis
MH  - Symporters/analysis/*genetics
PMC - PMC6996107
OTO - NOTNLM
OT  - SLC16A1-AS1
OT  - non-small cell lung cancer
OT  - prognosis
OT  - proliferation
COIS- Competing interests: None declared.
EDAT- 2019/08/03 06:00
MHDA- 2021/05/01 06:00
PMCR- 2020/02/03
CRDT- 2019/08/03 06:00
PHST- 2019/06/06 00:00 [accepted]
PHST- 2019/08/03 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2019/08/03 06:00 [entrez]
PHST- 2020/02/03 00:00 [pmc-release]
AID - jim-2019-001080 [pii]
AID - 10.1136/jim-2019-001080 [doi]
PST - ppublish
SO  - J Investig Med. 2020 Jan;68(1):52-59. doi: 10.1136/jim-2019-001080. Epub 2019 Jul 
      31.